A recent study on a novel, selective, nonsteroidal mineralocorticoid receptor antagonist, finerenone, also found potential for reducing AF risk in patients with chronic kidney disease and type 2 diabetes (43). Here, NR3C2 is linked to type 2 diabetes mellitus.